Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Meeting Highlights
Meeting Highlights
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Read More
Meeting Highlights
Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
Meeting Highlights
Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations
Read More
Meeting Highlights
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Read More
Meeting Highlights
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
Read More
Meeting Highlights
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
Meeting Highlights
Ceritinib Effective in Treating Brain Metastases in NSCLC
Read More
Meeting Highlights
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Read More
Meeting Highlights
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy
Read More
Meeting Highlights
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome
Read More
1
2
3
4
5
6
7
Page 4 of 17
Results 31 - 40 of 169